Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
Latest Forecast: Lots to discuss on competitive intelligence at Pharma CI
Somehow it is already September which means we’re preparing for one of the key events in the biopharma calendar, at least if you’re involved in competitive intelligence –…
Five Forces Fuelling Pharma’s Age of Uncertainty
We're putting the finishing touches to our annual World Preview report - the forecasts are fascinating, but there's much to be uncertain about in the current…
My Perfect Combination: Customers and Food
At the recent BIO International convention, I was able to combine two of my favourite things - talking to customers and an excellent meal!
Evaluate Omnium: An Award-Winning Decision
Evaluate Omnium is now officially an award-winning solution!
BioSci Deal of the Month - Kite & Arcellx
In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA.
Five Top Takeaways from BIO International 2023
A couple of weeks ago, we saw the return of BIO International to Boston for the first time since 2018.
In case you missed it: Three things we learned in our gene editing webinar
Missed our gene editing webinar? Fear not! Here are a few of the highlights from our panel of experts which included Verve Therapeutics’ CEO, Sekar Kathiresan as well as…
Meet the Evaluate Team – BIO International Special: Jon Moser
With close to 20 years’ service at Evaluate, Jon Moser is pretty much woven into the fabric of the company – and its products. Now in the role of Chief Innovation Officer…
Five Questions about the Future of Gene Editing
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a…
BioSci Deal of the Month - Spero Therapeutics & GSK
In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.